Neurocrine Bioscienc
(NBIX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2013 | 12-2012 | 09-2012 | 06-2012 | 03-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,075 | 5,025 | -4,465 | -1,387 | -886 |
| Depreciation Amortization | 814 | 3,792 | 2,961 | 1,808 | 775 |
| Accounts receivable | 14,090 | -12,878 | N/A | N/A | N/A |
| Other Working Capital | 12,928 | -13,671 | -866 | -1,653 | -2,579 |
| Other Operating Activity | -13,845 | -17,562 | -24,015 | -16,850 | -8,514 |
| Operating Cash Flow | $1,912 | $-35,294 | $-26,385 | $-18,082 | $-11,204 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -35,031 | -33,793 | -61,716 | -72,706 | -44,837 |
| PPE Investments | -46 | -939 | -904 | -622 | -379 |
| Other Investing Activity | 0 | -29 | -28 | 25 | 0 |
| Investing Cash Flow | $-35,077 | $-34,761 | $-62,648 | $-73,303 | $-45,216 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 966 | 83,702 | 83,414 | 83,296 | 83,253 |
| Financing Cash Flow | $966 | $83,702 | $83,414 | $83,296 | $83,253 |
| Beginning Cash Position | 63,754 | 50,107 | 50,107 | 50,107 | 50,107 |
| End Cash Position | 31,555 | 63,754 | 44,488 | 42,018 | 76,940 |
| Net Cash Flow | $-32,199 | $13,647 | $-5,619 | $-8,089 | $26,833 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,912 | -35,294 | -26,385 | -18,082 | -11,204 |
| Capital Expenditure | -59 | -971 | -929 | -594 | -404 |
| Free Cash Flow | 1,853 | -36,265 | -27,314 | -18,676 | -11,608 |